Patents Assigned to Women's and Children's Hospital
-
Patent number: 8735173Abstract: A novel protein profiling method of testing for Lysosomal Storage Diseases (“LSD”) using discovered normalized lysosomal fingerprint patterns. The fingerprint patterns reveal the health of lysosomal organelles, specific LSD, and clinical severity. Multiplexing bead technology for simultaneous screening of multiple LSD and normalizing measured enzyme activity or protein levels against other lysosomal proteins, enzymes, or enzyme activities. Compounds, reagents, and methods for identifying and quantifying multiple target enzymes and proteins.Type: GrantFiled: March 28, 2012Date of Patent: May 27, 2014Assignee: Women's and Children's HospitalInventors: Peter John Meikle, John Joseph Hopwood, Douglas Alexander Brooks, Caroline Dean
-
Publication number: 20120219531Abstract: The present application discloses a method of generating bone tissue in vivo comprising implanting cells into a human or animal at a location where bone growth is required, wherein the cells have been obtained by the in vitro suspension culture of mesenchymal stem cells attached to microcarriers.Type: ApplicationFiled: November 15, 2011Publication date: August 30, 2012Applicants: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH, NATIONAL UNIVERSITY OF SINGAPORE, KK WOMEN'S AND CHILDREN'S HOSPITALInventors: Steve Oh, Shaul Reuveny, Allen Chen, Jerry Kok Yen Chan, Zhiyong Zhang
-
Publication number: 20120184050Abstract: A novel protein profiling method of testing for Lysosomal Storage Diseases (“LSD”) using discovered normalized lysosomal fingerprint patterns. The fingerprint patterns reveal the health of lysosomal organelles, specific LSD, and clinical severity. Multiplexing bead technology for simultaneous screening of multiple LSD and normalizing measured enzyme activity or protein levels against other lysosomal proteins, enzymes, or enzyme activities. Compounds, reagents, and methods for identifying and quantifying multiple target enzymes and proteins.Type: ApplicationFiled: March 28, 2012Publication date: July 19, 2012Applicant: WOMEN'S AND CHILDREN'S HOSPITALInventors: Peter John Meikle, John Joseph Hopwood, Douglas Alexander Brooks, Caroline Dean
-
Patent number: 8173443Abstract: A novel protein profiling method of testing for Lysosomal Storage Diseases (“LSD”) using discovered normalized lysosomal fingerprint patterns. The fingerprint patterns reveal the health of lysosomal organelles, specific LSD, and clinical severity Multiplexing bead technology for simultaneous screening of multiple LSD and normalizing measured enzyme activity or protein levels against other lysosomal proteins, enzymes, or enzyme activities. Compounds, reagents, and methods for identifying and quantifying multiple target enzymes and proteins.Type: GrantFiled: March 31, 2004Date of Patent: May 8, 2012Assignee: Women's and Children's HospitalInventors: Peter John Meikle, John Joseph Hopwood, Douglas Alexander Brooks, Caroline Dean
-
Patent number: 7615224Abstract: Multiplexing bead technology is used for simultaneous screening of multiple LSD and normalizing measured enzyme activity or protein levels against other lysosomal proteins, enzymes, or enzyme activities. Diagnostic compositions include microspheres conjugated to purified antibodies that specifically bind LSD target antigens: saposin, LAMP-1, ?-iduronidase, ?-glucosidase, ?-glucosidase, 2-sulphatase, 4-sulphatase, ?-galactosidase, sphingomyelinase, 3-sulphatase or sulphamidase. The target antigens are naturally present in biological fluids or tissues of either LSD or non-LSD patients.Type: GrantFiled: December 1, 2005Date of Patent: November 10, 2009Assignee: Women's and Children's HospitalInventors: Peter John Meikle, John Joseph Hopwood, Douglas Alexander Brooks, Caroline Dean
-
Patent number: 7378231Abstract: The invention provides methods of diagnosing or monitoring lysosomal storage disorders based on detecting levels of saposins, LAMPs and/or ?-glucosidase in patient sample. Elevated levels of saposins and/or LAMPs are indicative of a disorder. Elevated levels of ? glucosidase are indicative of some types of lysosomal storage disorders and decreased levels of ? glucosidase are indicative of other types of lysosomal storage disorder. In some methods, the profile of elevation of different saposins, LAMPs and ? glucosidase allows distinction between different types of lysosomal storage disorder.Type: GrantFiled: March 17, 2000Date of Patent: May 27, 2008Assignee: Women's and Children's HospitalInventors: Peter John Meikle, John Joseph Hopwood, Bryan Gordon Winchester
-
Patent number: 7361481Abstract: Methods for assaying a lysosomal enzyme activity present in a blood sample obtained from a patient. The method combines the blood or plasma sample in a buffer with at least one binding reagent capable of reacting with alpha-glucosidase present in the blood sample to form an enzyme reagent complex. The lysosomal enzyme activity present in the blood sample is then determined from the enzyme reagent complex formed and compared to a mean level of alpha-glucosidase in a control population of individuals not having a lysosomal storage disease.Type: GrantFiled: October 26, 2004Date of Patent: April 22, 2008Assignee: Women's and Children's HospitalInventors: Peter John Meikle, John Joseph Hopwood, Bryan Gordon Winchester
-
Publication number: 20070265432Abstract: Multiplexing bead technology is used for simultaneous screening of multiple LSD and normalizing measured enzyme activity or protein levels against other lysosomal proteins, enzymes, or enzyme activities. Diagnostic compositions include microspheres conjugated to purified antibodies that specifically bind LSD target antigens: saposin, LAMP-1, ?-iduronidase, ?-glucosidase, ?-glucosidase, 2-sulphatase, 4-sulphatase, ?-galactosidase, sphingomyelinase, 3-sulphatase or sulphamidase. The target antigens are naturally present in biological fluids or tissues of either LSD or non-LSD patients.Type: ApplicationFiled: December 1, 2005Publication date: November 15, 2007Applicant: Women's and Children's HospitalInventors: Peter Meikle, John Hopwood, Douglas Brooks, Caroline Dean
-
Publication number: 20050250196Abstract: Chimeric carbohydrates produced by recombinant microorganism carrying exogenous glycosyl transferases act with or without exogenous enzymes required for synthesis or nucleotide synthesis precursors. These recombinant microorganism can be used as a means for competitively inhibiting the binding of toxins or adhesins to receptors of mucosal surfaces, especially gastrointestinal surface. In particular chimeric sugar moieties have been made for lipopolysaccharides, in recombinant microorganism that present multiple copies of the oligosaccharides. The oligosacchide moieties so presented act as receptor mimic for toxins and adhesins. A number have been synthesise and have been shown to confer protection against attack by pathogenic organisms or their products in vitro and an in vivo.Type: ApplicationFiled: December 20, 2004Publication date: November 10, 2005Applicants: Women's and Children's Hospital, Adelaide Research & Innovation Pty. Ltd.Inventors: Adrienne Paton, Renato Morona, James Paton
-
Publication number: 20050142590Abstract: Methods for assaying a lysosomal enzyme activity present in a blood sample obtained from a patient. The method combines the blood or plasma sample in a buffer with at least one binding reagent capable of reacting with alpha-glucosidase present in the blood sample to form an enzyme reagent complex. The lysosomal enzyme activity present in the blood sample is then determined from the enzyme reagent complex formed and compared to a mean level of alpha-glucosidase in a control population of individuals not having a lysosomal storage disease.Type: ApplicationFiled: October 26, 2004Publication date: June 30, 2005Applicant: Women's and Children's HospitalInventors: Peter Meikle, John Hopwood, Bryan Winchester
-
Patent number: 6833130Abstract: Chimeric carbohydrates produced by recombinant microorganism carrying exogenous glycosyltransferases act with or without exogenous enzymes required for synthesis or nucleotide synthesis precursors. These recombinant microorganism can be used for competitively inhibiting the binding of toxins or adhesins to receptors of mucosal surfaces, especially gastrointestinal surface. In particular chimeric sugar moieties have been made for lipopolysaccharides, in recombinant microorganism that present multiple copies of the oligosaccharides. The oligosaccharide moieties so presented act as receptor mimic for toxins and adhesins. A number have been synthesized and have been shown to confer protection against attack by pathogenic organisms or their products in vitro and in vivo.Type: GrantFiled: September 9, 2000Date of Patent: December 21, 2004Assignees: Women's and Children's Hospital, Adelaide Research & Innovation Pty. Ltd.Inventors: Adrienne W. Paton, Renato Morona, James C. Paton
-
Publication number: 20040191847Abstract: The present invention relates generally to lysosomal storage disorders and to diagnostic agents for their detection in humans and other animals. More particularly, the present invention is directed to the uses of the LSD markers Lamp-1, Lamp-2, Limp-II, 4-sulphatase, acid phosphatase (ACP), &bgr;-hexasaminidase or &agr;-mannosidase, amongst others as diagnotic agents for the detection of many lysosomal storage disorders.Type: ApplicationFiled: January 13, 2004Publication date: September 30, 2004Applicant: Women's and Children's HospitalInventors: Peter J. Meikle, Douglas A. Brooks, John J. Hopwood
-
Patent number: 6627745Abstract: The invention provides the nucleic acid sequence encoding the protein associated with familial Mediterranean fever (FMF). The cDNA sequence is designated as MEFV. The invention is also directed towards fragments of the DNA sequence, as well as the corresponding sequence for the RNA transcript and fragments thereof. Another aspect of the invention provides the amino acid sequence for a protein (pyrin) associated with FMF. The invention is directed towards both the full length amino acid sequence, fusion proteins containing the amino acid sequence and fragments thereof. The invention is also directed towards mutants of the nucleic acid and amino acid sequences associated with FMF. In particular, the invention discloses three missense mutations, clustered in within about 40 to 50 amino acids, in the highly conserved rfp (B30.2) domain at the C-terminal of the protein. These mutants include M6801, M694V, K695R, and V726A.Type: GrantFiled: August 7, 2000Date of Patent: September 30, 2003Assignees: The United States of America as represented by the Department of Health and Human Services, Cedars-Sinai Medical Center, University of California, University of Michigan, Women's and Children's Hospital, Heller Institute for Medical ResearchInventors: Daniel L. Kastner, Ivona Aksentijevichh, Michael Centola, Zuoming Deng, Ramen Sood, Francis S. Collins, Trevor Blake, P. Paul Liu, Nathan Fischel-Ghodsian, Deborah L. Gumucio, Robert I. Richards, Darrell O. Ricke, Norman A. Doggett, Mordechai Pras
-
Patent number: 6541254Abstract: The present invention provides a highly glycosylated iduronate-2-sulfatase enzyme comprising an iduronate-2-sulfatase polypeptide with at least 5 kilodalton (kDa) more sugar than iduronate-2-sulfatase purified from a natural source, e.g. human liver. The present invention also provides an enzymatically active polypeptide fragment or variant of such a highly glycosylated iduronate-2-sulfatase. The present invention further provides an isolated nucleic acid encoding iduronate-2-sulfatase, as well as an expression vector, a host cell and a method for producing the present highly glycosylated iduronate-2-sulfatase enzyme.Type: GrantFiled: October 10, 2000Date of Patent: April 1, 2003Assignee: Women's and Children's HospitalInventors: Peter J. Wilson, Charles Phillip Morris, Donald Stewart Anson, Teresa Occhiodoro, Julie Bielicki, Peter Roy Clements, John Joseph Hopwood
-
Patent number: 6524835Abstract: The present invention relates generally to &agr;-L-iduronidase and to genetic sequences encoding same. More particularly, the present invention provides an isolated nucleic acid molecule comprising a sequence of nucleotides which encodes or are complementary to a sequence which encodes a mammalian &agr;-L-iduronidase or fragment or derivative thereof and to the recombinant enzyme encoded thereby. These molecules are useful in the investigation, diagnosis and treatment of subjects suspected of or suffering from &agr;-L-iduronidase deficiency.Type: GrantFiled: August 16, 2000Date of Patent: February 25, 2003Assignee: Women's and Children's HospitalInventors: Hamish Steel Scott, Donald Stewart Anson, Annette Marie Orsborn, Paul Victor Nelson, Peter Roy Clements, Charles Phillip Morris, John Joseph Hopwood
-
Patent number: 6491913Abstract: The present invention relates generally to mammalian sulphamidase and to genetic sequences encoding same and to the use of these in the investigation, diagnosis and treatment of subjects suspected of or suffering from sulphamidase deficiency.Type: GrantFiled: December 4, 2000Date of Patent: December 10, 2002Assignee: Women's and Children's HospitalInventors: John Joseph Hopwood, Hamish Steele Scott, Craig Geoffrey Freeman, Charles Phillip Morris, Lianne Cheryl Blanch, Xiao Hui Guo
-
Patent number: 6458579Abstract: The present invention relates generally to mammalian sulphamidase and to genetic sequences encoding same and to the use of these in the investigation, diagnosis and treatment of subjects suspected of or suffering from sulphamidase deficiency.Type: GrantFiled: December 4, 2000Date of Patent: October 1, 2002Assignee: Women's and Children's HospitalInventors: John Joseph Hopwood, Hamish Steele Scott, Craig Geoffrey Freeman, Charles Phillip Morris, Lianne Cheryl Blanch, Xiao Hui Guo
-
Patent number: 6262119Abstract: Method of treating or ameliorating symptoms of T-cell mediated disease wherein a composition comprising a therapeutically effective amount of a polyunsaturated fatty acid and a pharmaceutically acceptable carrier is administered to the patient. The polyunsaturated fatty acid contains 18-25 carbon atoms, 1-6 double bonds and has 1 or 2 substitutions selected from &bgr; oxa, &ggr; oxa, &bgr; thia and &ggr; thia, based on the fatty acid acyl carbon atom, or the polyunsaturated fatty acid contains 16-26 carbon atoms, 3-double bonds and is covalently coupled at the carboxylic acid group to an amino acid.Type: GrantFiled: April 12, 1999Date of Patent: July 17, 2001Assignees: Peptide Technology Limited, Women's and Children's Hospital AdelaideInventors: Antonio Ferrante, Alfred Poulos, Michael Joseph Pitt, Christopher John Easton, Merilyn Joy Sleigh, Deborah Ann Rathjen, Fred Widmer
-
Patent number: 6255096Abstract: The present invention relates generally to mammalian &agr;-N-acetyglucosaminidase and to genetic sequences encoding same and to their use in the investigation, diagnosis and treatment of subjects suspected of or suffering from &agr;-N-acetylglucosaminidase deficiency.Type: GrantFiled: April 22, 1999Date of Patent: July 3, 2001Assignee: Women's and Children's HospitalInventors: John Joseph Hopwood, Hamish Steele Scott, Birgit Weber, Lianne Blanch, Donald Stewart Anson
-
Patent number: 6242576Abstract: The DNA sequence spanning the fragile X site on the X human chromosome has been obtained in purified and isolated form. As fragile X is associated with mental retardation, the availability of a DNA which spans this locus permits diagnosis and treatment of the related mental disorders. Polyclonal and monoclonal antibodies to an amino acid sequence encoded by SEQ ID NO:1, a DNA sequence from the Fragile X site, are also disclosed.Type: GrantFiled: June 2, 1995Date of Patent: June 5, 2001Assignees: Women's and Children's Hospital, Washington UniversityInventors: Grant R. Sutherland, Robert I. Richards, David Schlessinger, Ramaiah Nagaraja, Eric J. Kremer, Sui Yu, Elizabeth Baker, John C. Mulley, Jean-Louis Mandel, Melanie April Pritchard, Michael Lynch